Financial performance 2008/2007
Download Excel table (see terms of use page)
OUR FINANCIAL PERFORMANCE| 2008 | 2007 | 2006 | 2008 compared to 2007 | 2007 compared to 2006 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth % |
Reported growth % |
CER growth % |
Reported growth % |
| Merrem | 897 | 97 | 27 | 773 | 121 | 48 | 604 | 13 | 16 | 20 | 28 |
| Synagis1 | 1,230 | 612 | – | 618 | 618 | – | – | n/m | n/m | n/m | n/m |
| FluMist1 | 104 | 51 | – | 53 | 53 | – | – | n/m | n/m | n/m | n/m |
| Other | 220 | (54) | 4 | 270 | (12) | 11 | 271 | (20) | (19) | (4) | – |
| Total | 2,451 | 706 | 31 | 1,714 | 780 | 59 | 875 | 41 | 43 | 89 | 96 |
| 1 Acquired in June 2007. | |||||||||||
PERFORMANCE 2008
Reported performance
Total Infection sales increased on a reported basis by 43% to $2,451 million as a full year of Synagis and FluMist sales were taken in the Group for the first time, and Merrem sales enjoyed another year of good growth.
Performance – CER growth rates
Infection sales were up 41% at CER. For the full year, Synagis sales were $1,230 million. Sales in 2007 were $618 million, but this only reflected sales since the acquisition of MedImmune in June 2007. Worldwide sales of Synagis in the fourth quarter were $506 million, a 5% increase over the same period in 2007 when the product was included in sales.
FluMist sales were $104 million for the full year. In contrast to 2008, all of 2007 FluMist sales of $53 million were realised in the fourth quarter as a result of the timing of regulatory approvals for the new formulation and expanded label.
PERFORMANCE 2007
Reported performance
Infection sales grew by 96% to $1,714 million from $875 million in 2006, driven by the inclusion of seven months of Synagis and FluMist sales and an increase in Merrem sales of 28%.
Performance – CER growth rates
Infection sales grew by 89%, after excluding the effect of exchange. CER growth of 20% from Merrem, with sales of $773 million, and the inclusion of Synagis and FluMist were the principal drivers of this growth. Sales of Synagis totalled $618 million for the period post-acquisition of MedImmune, with $480 million arising in the fourth quarter. Synagis sales are highly seasonal, with the majority of sales recorded in the fourth and first quarters.
Sales of FluMist were $53 million for the full year, all of which were recorded in the fourth quarter. As with Synagis, there were no corresponding sales in the prior year period.
Sales of Merrem increased by 20% to $773 million, with strong growth in the US (sales up 32% to $149 million) and Western Europe (sales up 20% to $307 million).
